Losy J, Michałowska-Wender G, Wender M
Zakładu Neuroimmunologii Klinicznej Katedry Neurologii AM w Poznaniu.
Neurol Neurochir Pol. 2001 Jul-Aug;35(4):583-8.
Chemokines: MCP-1 and MIP-1 alpha may play an important role in the pathogenesis of multiple sclerosis, influencing migration of lymphocytes to the CNS. One of possible mechanisms of interferon beta action may be an effect on chemokines. We measured MCP-1 and MIP-1 alpha chemokines in sera of 24 patients with MS treated with interferon beta-1a before and after 3 months of therapy and in 15 control patients. There was a significant increase of MIP-1 alpha concentration in sera of MS patients in comparison with control group. After 3 months of therapy with interferon beta-1a, MIP-1 alpha and MCP-1 levels did not differ from the values before therapy. Investigations will be continued after longer time of treatment with interferon beta.
单核细胞趋化蛋白-1（MCP-1）和巨噬细胞炎性蛋白-1α（MIP-1α）可能在多发性硬化症的发病机制中发挥重要作用，影响淋巴细胞向中枢神经系统的迁移。β-干扰素作用的一种可能机制可能是对趋化因子的影响。我们检测了24例接受β-1a干扰素治疗的多发性硬化症患者在治疗前和治疗3个月后的血清中MCP-1和MIP-1α趋化因子，以及15例对照患者血清中的趋化因子。与对照组相比，多发性硬化症患者血清中MIP-1α浓度显著升高。在用β-1a干扰素治疗3个月后，MIP-1α和MCP-1水平与治疗前的值没有差异。在用β-干扰素进行更长时间的治疗后，研究将继续进行。
